Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
News and press releases about Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) highlight its evolution as a biopharmaceutical and technology company, its cell therapy platforms, and its corporate transactions. Company announcements describe Coeptis as operating biopharmaceutical divisions focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, alongside a Technology Division built around AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group.
Recent news has emphasized developments in Coeptis’ pipeline and partnerships. The company has reported securing exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform and forming GEAR Therapeutics, Inc. to advance GEAR-modified NK cells for a broad range of cancers. SNAP Biosciences, a majority-owned subsidiary, has announced a licensing agreement with Monarch Therapeutics to enhance the SNAP-CAR NK cell therapy platform using small-molecule adaptor technology.
Coverage also includes updates on Coeptis’ hybrid business model and technology initiatives. Articles describe how the NexGenAI platform contributes revenue while the company advances its cell therapy research, and how a co-working technology hub in India supports AI, blockchain, and digital transformation projects for the NexGenAI Affiliates Group.
Another key theme in recent news is corporate strategy and capital structure. Coeptis has announced the extinguishment of a convertible note with YA II PN, Ltd, and multiple releases detail a proposed merger with Z Squared Inc., a Dogecoin-focused digital asset mining company. These items cover the filing and effectiveness of a Form S-4 registration statement, the planned spin-out of biopharmaceutical operations, and the intention for the combined company to focus on digital asset mining. Investors and observers can use this news stream to follow Coeptis’ biopharmaceutical progress, technology partnerships, financing actions, and the status of its planned merger with Z Squared.
Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has announced the expansion of its technological initiatives to include artificial intelligence and blockchain solutions. Following the successful launch of its Technology Division, the company aims to enhance operational efficiency and customer engagement through these advanced technologies.
CEO Dave Mehalick expressed enthusiasm about building upon the momentum generated by their Technology Division, particularly in AI, while exploring blockchain opportunities. The company views this expansion as a strategic move to remain at the forefront of technological developments and adapt to the evolving digital marketplace.
Coeptis Therapeutics Holdings (Nasdaq: COEP) announced it has regained compliance with Nasdaq's Listing Rule 5550(a)(2), known as the 'Bid Price Rule', following the Nasdaq Hearings Panel's decision from September 17, 2024. This development represents a positive start for the biopharmaceutical company, which focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the initial rollout of its NexGenAI Affiliates Network platform, securing five new customers with a total contract value of $1.7 million. The company has signed multiple Managed Services Agreements valued at $1.25 million with an anticipated recurring monthly revenue stream of $450,000.
The NexGenAI platform integrates AI-driven marketing software, robotic process automation (RPA), and data analytics to optimize campaigns and streamline operations. The platform features include AI Dialer Service, AI SMS Service, and RPA Assistance for marketing, recruitment, investment, and affiliate services.
CEO Dave Mehalick expressed optimism about the platform's early adoption and outlined plans for rapid rollout throughout 2025. The company expects significant growth through additional contracts with prospective clients currently under discussion.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a 1-for-20 reverse stock split effective December 31, 2024. Upon implementation, every 20 shares of outstanding common stock will be converted into one share, with fractional shares rounded up to the next whole number. The reverse split aims to help the company meet Nasdaq Capital Market's minimum bid price requirement of $1.00 per share.
The split was approved by stockholders on December 18, 2024, and will not alter stockholders' percentage interest in the company's outstanding common stock, except for adjustments from fractional share treatment. Continental Stock Transfer is serving as the exchange agent, with stockholders holding shares in brokerage accounts not required to take any action.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the acquisition of the NexGenAI Affiliates Network platform and launched Coeptis Technologies, marking a strategic expansion into AI-powered solutions. The platform, developed by NexGenAI Solutions Group, provides AI-powered marketing software and robotic process automation (RPA) capabilities designed for the biotech, pharmaceutical, and multi-level marketing industries.
The acquisition aims to enhance marketing optimization, customer engagement, and operational efficiency in highly regulated sectors. The company views this integration as a strategic move to leverage advanced technologies within the biopharmaceutical sector and provide innovative tools for companies facing marketing challenges in competitive industries.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the launch of Coeptis Technologies, a new division aimed at diversifying its business beyond biopharmaceuticals. The company has signed a binding Letter of Intent to acquire key assets from a Risk Mitigation Software Company with 10,000 customers across 100 countries.
The acquisition includes proprietary technologies such as Data Placement Manager and Sensitive Content Manager solutions. This move follows the upcoming acquisition of NexGenAI Affiliates Network, positioning Coeptis in the data security and AI technology sectors. The Risk Mitigation Software Company's CEO will join Coeptis to lead the new technology division, with the transaction expected to close in early 2025.
Coeptis Therapeutics Holdings (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, a platform offering AI-powered marketing software and robotic process automation (RPA) capabilities. The acquisition aims to enhance Coeptis's operational efficiency while maintaining its focus on biopharmaceutical innovation. NexGenAI's suite of marketing tools utilizes AI and RPA to optimize campaigns, streamline workflows, and generate insights, particularly targeting the biotech, pharmaceutical, and multi-level marketing industries. The platform helps companies manage marketing campaigns while maintaining regulatory compliance.
Coeptis Therapeutics announced the acceptance of Phase 1 study results for DVX201, an allogeneic natural killer (NK) cell therapy, in Molecular Therapy Methods and Clinical Development. The study evaluated DVX201 for treating hospitalized COVID-19 patients at high risk for disease progression. Key findings showed DVX201 was safe and well-tolerated in 9 patients, with no dose-limiting toxicities or cytokine release syndrome. The therapy, derived from pooled donor cord blood CD34+ cells, demonstrated rapid improvements in oxygenation, improved pulmonary radiographic findings, and led to hospital discharge within days of infusion.
Coeptis Therapeutics Holdings (Nasdaq: COEP) has expanded its license agreement with Deverra Therapeutics to include pandemic preparedness and emergency use applications for their allogeneic natural killer (NK) cell technology. The expanded license now covers the use of unmodified NK cells for treating viral infections, pandemic-related illnesses, and emergency stockpiling. This builds upon their August 2023 agreement, which included an allogeneic stem cell expansion platform, two IND applications, and two Phase 1 clinical trials investigating DVX201 as an unmodified NK cell therapy.
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), a biopharmaceutical company developing innovative cell therapy platforms, announced that its Chief Scientific and Medical Officer, Dr. Colleen Delaney, will present at several upcoming fall conferences. These events include:
- 2024 AABB Annual Meeting (October 19-22, Houston, TX)
- ASHI 50th Annual Meeting (October 21-24, Anaheim, CA)
- Advanced Therapies USA Congress (November 12-13, Philadelphia, PA)
- Donor Selection & Cell Source Summit (November 18-20, San Diego, CA)
The conferences provide an opportunity to showcase Coeptis' advancements in universal cell therapy for cancer, autoimmune, and infectious diseases. CEO Dave Mehalick emphasized the importance of these events in building momentum for their work on off-the-shelf universal allogeneic therapies, which aim to revolutionize cell therapy by lowering treatment costs and improving access to life-saving treatments.